 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.             *sb0921*      
SENATE BILL 921  
J5, J4    5lr3400  
    CF HB 1087  
By: Senator Gile  
Introduced and read first time: January 28, 2025  
Assigned to: Finance  
Committee Report: Favorable with amendments  
Senate action: Adopted  
Read second time: March 10, 2025  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Health Insurance – Step Therapy or Fail –First Protocols – Drugs to Treat 2 
Associated Conditions of Advanced Metastatic Cancer  3 
 
FOR the purpose of prohibiting certain insurers, nonprofit health service plans, and health 4 
maintenance organizations from imposing a step therapy or fail –first protocol on 5 
certain prescription drugs used  prescribed by a treating physician  to treat a 6 
sympt om of or a side effect from treatment of certain metastatic cancer under certain 7 
circumstances; and generally relating to step therapy and fail –first protocols and 8 
health insurance.  9 
 
BY repealing and reenacting, without amendments,  10 
 Article – Insurance  11 
Section 15 –142(a)(1) and (4) and (b)  12 
 Annotated Code of Maryland  13 
 (2017 Replacement Volume and 2024 Supplement)  14 
 
BY repealing and reenacting, with amendments,  15 
 Article – Insurance  16 
Section 15 –142(e)  17 
 Annotated Code of Maryland  18 
 (2017 Replacement Volume and 2024 Supplement)  19 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 20 
That the Laws of Maryland read as follows:  21 
 
2 SENATE BILL 921   
 
 Article – Insurance  1 
 
15–142. 2 
 
 (a) (1) In this section the following words have the meanings indicated.  3 
 
  (4) (i) “Step therapy or  fail–first protocol” means a protocol established 4 
by an insurer, a nonprofit health service plan, or a health maintenance organization that 5 
requires a prescription drug or sequence of prescription drugs to be used by an insured or 6 
an enrollee before a pre scription drug ordered by a prescriber for the insured or the enrollee 7 
is covered.  8 
 
   (ii) “Step therapy or fail –first protocol” includes a protocol that 9 
meets the definition under subparagraph (i) of this paragraph regardless of the name, label, 10 
or termi nology used by the insurer, nonprofit health service plan, or health maintenance 11 
organization to identify the protocol.  12 
 
 (b) (1) This section applies to:  13 
 
   (i) insurers and nonprofit health service plans that provide hospital, 14 
medical, or surgical benef its to individuals or groups on an expense –incurred basis under 15 
health insurance policies or contracts that are issued or delivered in the State; and  16 
 
   (ii) health maintenance organizations that provide hospital, 17 
medical, or surgical benefits to individu als or groups under contracts that are issued or 18 
delivered in the State.  19 
 
  (2) An insurer, a nonprofit health service plan, or a health maintenance 20 
organization that provides coverage for prescription drugs through a pharmacy benefits 21 
manager is subject t o the requirements of this section.  22 
 
 (e) An entity subject to this section may not impose a step therapy or fail –first 23 
protocol on an insured or an enrollee for a prescription drug approved by the U.S. Food and 24 
Drug Administration if:  25 
 
  (1) (I) the presc ription drug is used to treat the insured’s or enrollee’s 26 
stage four advanced metastatic cancer; and  27 
 
  [(2)] (II) use of the prescription drug is:  28 
 
   [(i)] 1. consistent with the U.S. Food and Drug  29 
Administration –approved indication or the National Comprehensive Cancer Network 30 
Drugs & Biologics Compendium indication for the treatment of stage four advanced 31 
metastatic cancer; and  32 
 
   [(ii)] 2. supported by peer –reviewed medical literature ; OR 33 
 
 SENATE BILL 921  3 
 
   (2) (I) THE PRESCRIPTION DRU G IS USED  PRESCRIBED BY A 1 
TREATING PHYSICIAN  TO TREAT A SYMPTOM O F OR A SIDE EFFECT F ROM 2 
TREATMENT OF THE INS URED’S OR ENROLLEE ’S STAGE FOUR ADVANCE D 3 
METASTATIC CANCER THAT THE TREATING PR OVIDER  DETERMINES WILL 4 
NEGATIVELY IMPACT TH E INSURED ’S OR ENROLLEE ’S HEALTH IF  LEFT UNTREATED ; 5 
AND  6 
 
   (II) USE OF THE PRESCRIPT ION DRUG IS : 7 
 
    1. CONSISTENT WITH BEST  PRACTICES FOR THE 8 
TREATMENT OF STAGE F OUR ADVANCED METASTA TIC CANCER , A CONDITION 9 
ASSOCIATED WITH STAG E FOUR ADVANCED META STATIC CANCER , OR A SIDE EFFECT 10 
ASSOCIATED WITH STAG E FOUR  ADVANCED METASTATIC CANCER TREATMENT ; AND 11 
 
    2. SUPPORTED BY PEER –REVIEWED MEDICAL 12 
LITERATURE ; AND 13 
 
   (III) THE PRESCRIPTION DRU G IS COVERED UNDER T HE TERMS 14 
OF THE POLICY OR CON TRACT OF THE INSURED  OR ENROLLEE . 15 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to all 16 
policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or 17 
after January 1, 2026.  18 
 
 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect 19 
January 1, 2026.  20 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
                 President of the Senate.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  